Pharma Intelligence is part of the Business Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Construct winning strategies that anticipate where value will lie. In Vivo’s up-to-the-minute intelligence spans important deals, drug approval rates, regulatory issues, pricing and reimbursement.
How it works
With In Vivo, you get a window into what the key players in the biopharma, medtech, and diagnostics industries are thinking, as well as what your competitors are doing.
And if you need to need to find out more about developments or trends to support presentations, proposals or business-critical decisions, you can access our global expert analysts through the Ask the Analyst service.
How In Vivo can help
You’ll benefit from:
Incisive projections of future industry advances
Analysis of trends shaping the market landscape
Access interviews with leading decision makers, industry experts and thought leaders, across the industry.
Put your questions about any of our news stories, data and analysis to our expert journalists and analysts.
What's successful, what are the trends
Trialtrove, In Vivo
13 Jul 2017
Imagine a world where you can print out your own medicine at home...
Topic Personalized Medicine
In Vivo
By Peter Charlish 10 Jul 2017
Liquid biopsies look set to revolutionize the management of cancer patients. A significant application could come in immuno-oncology.
Topic Cancer Business strategies
In Vivo
26 Jun 2017
The essential information in this free video comes to you from In Vivo, part of the Informa Pharma Intelligence suite of tools.
Topic Personalized Medicine
In Vivo
By Doro Shin 05 Jun 2017
Success rates are higher for clinical trials that incorporate selective pharmacogenomics and pharmacogenetics (PGX) biomarkers, according to data from Informa's Trialtrove.
Topic Personalized Medicine
In Vivo
By Michael Swanick 04 Jun 2017
The shifts roiling the health care industry are creating an entirely new commercial landscape. PwC says that the way pharma companies opt to address three pivotal challenges
Topic Personalized Medicine
In Vivo
By William Looney 04 Jun 2017
Personalized medicine is focused on meeting patients’ needs, but it also has the potential to transform the delivery and financing of health care.
Topic Personalized Medicine
In Vivo
By Peter Charlish 04 Jun 2017
Flatiron Health was formed to exploit a previously untapped source of real-world data on the treatment and clinical outcomes of cancer patients.
Topic Personalized Medicine
In Vivo
By Peter Charlish 04 Jun 2017
Singulex and Qiagen have entered a strategic alliance whereby Qiagen will be able to offer its clients companion diagnostic development services.
Topic Personalized Medicine
In Vivo
By Melanie Senior 04 Jun 2017
Artificial intelligence won’t transform pharma R&D, at least not anytime soon. But it is already impacting health care delivery and clinical trials.
Topic Personalized Medicine
In Vivo
By Melanie Senior 04 Jun 2017
Patient-centric R&D is imperative for pharma in delivering effective medicines and better outcomes.
Topic Personalized Medicine
In Vivo
By John Hodgson 17 May 2017
Oncology innovation: lots of drugs, lots of trials, sometimes not enough patients. And styles of innovation depend on whether a company has a big franchise to defend or would like one. In Vivo presents current data on sales, pipelines, trials and fails.
Topic Personalized Medicine
In Vivo
By William Looney 18 Apr 2017
The US Veterans Administration is attracting more interest from drugmakers seeking to grow their foothold in the lucrative – but scientifically challenging – market for CNS disorders.
Topic Research
In Vivo
By Jessica Lee; Ravi Patel; David Ruch 31 Mar 2017
Personalized medicine is becoming the hallmark of care in oncology, but its use is also increasing in other therapeutic areas including inflammation, respiratory, infectious diseases and central nervous system disorders, as scientific understanding of these diseases advances. The expansion of companion diagnostics beyond oncology has impacts on dealmaking, clinical practice and the R&D pipeline.
In Vivo
30 Mar 2017
Free article: What In Vivo has been saying about personalized medicine in this century.
In Vivo
By Lucie Ellis 22 Feb 2017
What is next for the treatment of cystic fibrosis, a rare disease market that has boomed in recent years on the back of new drug approvals with hefty price tags? Pipelines are full, but securing reimbursement is a challenge.
Topic Clinical trials
In Vivo
19 Jul 2017
In Vivo
19 Jul 2017
In Vivo
17 Jul 2017
In Vivo
17 Jul 2017
In Vivo
12 Jul 2017
In Vivo
12 Jul 2017
In Vivo
12 Jul 2017
In Vivo
12 Jul 2017
In Vivo
10 Jul 2017
In Vivo
10 Jul 2017
In Vivo
10 Jul 2017
In Vivo
05 Jul 2017
In Vivo
30 Jun 2017
In Vivo
30 Jun 2017
In Vivo
25 Jun 2017
+26 year(s) experience
Request a Trial
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
How can we help you?
Our team is always happy to hear from you. Please call us at:
Report store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
